

Appl. No. 10/694,978  
Amdt. dated January 27, 2006  
Reply to Office action of 10/27/2005

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

**Listing of Claims:**

Claims 1-20. (Cancelled).

Claim 21. (Currently Amended) An isolated or purified binding compound comprising an antigen binding site of an antibody that specifically binds to SEQ ID NOs: 2 or 4.

Claim 22. (Currently Amended) The binding compound of Claim 21 that is:

- a) a polyclonal antibody;
- b) a monoclonal antibody;
- c) a humanized antibody;
- d) an Fv, Fab, or F(ab')<sub>2</sub> fragment;
- e) glycosylated;
- f) attached to a carrier or a solid substrate; or
- g) detectably labeled.

Claim 23. (Currently amended) A binding composition comprising the binding compound of Claim 21, and a carrier, wherein the carrier is:

- a) an aqueous compound, ~~including water, saline, or buffer~~, or
- b) formulated for oral, rectal, nasal, topical, parenteral, subcutaneous, intramuscular, intravenous, or intradermal administration.

Claim 24. (Currently amended) A kit comprising the binding compound of Claim 21 and:

- a) a compartment;
- b) instructions for use; ~~or~~and
- c) a source of the polypeptide of SEQ ID NOs:2 or 4.

Appl. No. 10/694,978  
Amdt. dated January 27, 2006  
Reply to Office action of 10/27/2005

Claim 25. (Currently amended) A method of making the binding compound of Claim 21, comprising immunizing an animal with an immunogenic amount of the a polypeptide of SEQ ID NOs:2 or 4, or an antigenic fragment thereof.

Claim 26. (Canceled)

Claim 27. (Currently amended) A method of producing an antigen:antibody complex, comprising contacting the a polypeptide of having the amino acid sequence of SEQ ID NOs:2 or 4 with the antibody of Claim 22, thereby allowing the complex to form.

Claim 28. (Withdrawn) A method of modulating a cell involved in an inflammatory response comprising contacting the cell with:

- a) an agonist of SEQ ID NOs:2 or 4; or
- b) an antagonist of SEQ ID NOs:2 or 4.

Claim 29. (Withdrawn) The method of Claim 28, wherein:

- a) the agonist comprises SEQ ID NOs:2 or 4; or
- b) the antagonist comprises an antigen binding site of an antibody that specifically binds to SEQ ID NOs:2 or 4.

Claim 30. (Withdrawn) The method of Claim 28, wherein:

- a) the cell is a fibroblast or keratinocyte; or
- b) the response is psoriasis.

Claim 31. (Withdrawn) A method of treating a subject suffering from an inflammatory response or immunological disorder comprising administering an effective amount of:

- a) an agonist of SEQ ID NOs:2 or 4; or
- b) an antagonist of SEQ ID NOs:2 or 4.

Claim 32. (Withdrawn) The method of Claim 31, wherein:

- a) the agonist comprises SEQ ID NOs:2 or 4; or

Appl. No. 10/694,978  
Amndt. dated January 27, 2006  
Reply to Office action of 10/27/2005

b) the antagonist comprises an antigen binding site of an antibody that specifically binds to SEQ ID NOs:2 or 4.

Claim 33. (Withdrawn) The method of Claim 31, wherein the response or disorder comprises:

- a) fibroblast or keratinocyte response; or
- b) psoriasis.

Claim 34 (New) The binding composition of Claim 23, wherein the aqueous compound is:

- a) water;
- b) saline; or
- c) a buffer